1. Chou T-C, Zhang X-G, Balog A, Su D-S, Meng D, Savin K, Bertino JR, Danishefsky SJ (1998) Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 95: 9642–9647
2. Goldspiel BR (1997) Clinical overview of the taxanes. Pharmacotherapy 17: 110S–125S
3. Graff J, Smith DC, Neerukonda L, Alonso M, Edgar A, Wang Y, Beer TM, The Prostate Cancer Clinical Trials Consortium (2008) Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer 44th ASCO Annual Meeting, Chicago, Illinois, USA, May 30–June 3, Poster
4. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68: 5301–5308
5. Horwitz SB, Cohen D, Rao S, Ringel I, Shen H-J, Yang C-PH (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 15: 55–61